Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > The Claritas Patent...

<< Previous

Bullboard Posts

Next >>

Post by MyBuddyyon Mar 28, 2021 2:20pm

236 Views

Post# 32895233

The Claritas Patent...

I looked up the SaNOtize patent and they seem to have the nasal spray locked down. When I looked up Claritas it states they CAN patent anywhere where it's "open". Other than that they only have the NO injection covered.

Does anyone have any different or better search results??? I hope

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing